Accueil › Leucémie lymphocytaire chronique › Washington › Seattle
Essais cliniques pour Leucémie lymphocytaire chronique à Seattle, WA
20 études pour Leucémie lymphocytaire chronique recherchent des participants dans et autour de Seattle (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- et 1 autres
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Recrutement en coursPhase 1/2
- Research Site, Seattle
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Recrutement en coursPhase 3
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- et 1 autres
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Recrutement en coursPhase 3
- Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Recrutement en coursPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Recrutement en coursPhase 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Recrutement en coursPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recrutement en coursPhase 3
- Fred Hutchinson Cancer Research Center, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Recrutement en coursPhase 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Recrutement en coursPhase 2
- Fred Hutchinson Cancer Center, Seattle
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Recrutement en coursPhase 1
- Fred Hutch Cancer Center, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Recrutement en coursPhase 2Volontaires sains bienvenus
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Recrutement en coursPhase 4
- Swedish Cancer Institute, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Recrutement en coursPhase 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center, Seattle
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Recrutement en coursPhase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Recrutement en coursPhase 1
- Swedish Cancer Institute, Seattle
Essais pour Leucémie lymphocytaire chronique dans d'autres villes
- Boston, MA31 études
- Columbus, OH28 études
- Durham, NC27 études
- Washington, DC22 études
- Rochester, MN19 études
- New York City, NY18 études
- Houston, TX17 études
- Baldwin Park, CA16 études
- Milwaukee, WI15 études
- Cincinnati, OH14 études
- Chicago, IL14 études
- Nashville, TN13 études
Autres études à Seattle
- Cancer du poumon non à petites cellules53 études
- Cancer (tous types)49 études
- Cancer de la prostate42 études
- Leucémie aiguë myéloïde40 études
- Cancer du sein39 études
- Cancer métastatique39 études
- Cancer colorectal34 études
- Cancer du poumon33 études
- Cancer de l'ovaire30 études
- Myélome multiple22 études
- Syndromes myélodysplasiques21 études
- Leucémie aiguë lymphoblastique21 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.